Results of the economic evaluation of the first study: A multinational prospective economic evaluation

International Journal of Technology Assessment in Health Care

Volumn 12, Issue 4, 1996, Pages 698-713

  Schulman, Kevin A ^a   Buxton, Martin ^b   Click, Henry ^c   Sculpher, Mark ^b   Guzman, Gladys ^a   Kong, Janet ^a   Backhouse, Martin ^d   Mauskopf, Jo ^e   Bell, Larry ^e   Eisenberg, John M ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b BRUNEL UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Burroughs Wellcome Co ^*

^e Burroughs Wellcome Co   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTACYCLIN; PROSTACYCLIN DERIVATIVE;

CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DISEASE ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; REVIEW; SOCIOECONOMICS;

EID: 12644264311     PISSN: 02664623     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0266462300010989     Document Type: Review

References (23)

1. Backhouse, M. B., Mauskopf, J. A., Jones, D., et al. Economic outcomes of colfosceril palmitate rescue theapy in infants weighing 1250g or more with respiratory distress syndrome: Results from a randomized trial. Pharmacoeconomics, 1994, 4, 358-69.
2. Cohn, J. N., Archibald, D. G., Ziesche, S., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: Results of a Veterans Administration Cooperative Study. New England Journal of Medicine, 1986, 314, 1547-52.
3. Drummond, M. F., Stoddart, G. L., & Torrance, G. W. Methods for the Evaluation of Health Care Programs. New York: Oxford Medical Publications, 1987.
4. Dudley, R. A., Harrell, F. E., Smith, L. R., et al. Comparison of analytic models for estimating the effects of clinical factors on the cost of coronary artery bypass graft surgery. Journal of Clinical Epidemiology, 1993, 329, 546-51.
5. Efron, B. Better bootstrap confidence intervals. Journal of the American Statistical Association, 1987, 82, 171-200.
6. Efron, B., & Gong, G. A leisurely look at the bootstrap, jackknife and cross-validation. American Statistician, 1983, 37, 36-48.
7. Eisenberg, J. M., Schulman, K. A., Glick, H., & Koffer, H. Pharmacoeconomics: Economic evaluation of pharmaceuticals. In B. L. Strom (ed.), Pharmacoepidemiology. New York: Churchill Livingstone, 1989, 469-93.
8. Fenn, P., McGuire, A., Phillips, V., et al. The analysis of censored treatment cost data in economic evaluation. Medical Care, 1995, 33, 851-61.
9. Fryback, D. G. QALYs, HYEs, and the loss of innocence (editorial). Medical Decision Making, 1993, 271-72.
10. Guidelines for Economic Evaluation of Pharmaceuticals. Ottawa, Ontario: Canadian Coordinating Office for Health Technology Assessment, 1994, 17.
11. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee. Australia: Commonwealth Department of Health, Housing, and Community Services, 1992.
12. Harrell, F. E., Lee, K. L., & Mark, D. B. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statistics in Medicine, In press.
13. Health Care Financing Administration. Revisions to payment policies and adjustments to the relative value units under the physician fee schedule for calendar year 1994: Final rule. Federal Register, December 2, 1993, 58, 63689-839.
14. Kalbfleish, J. D., & Prentice, R. L. The statistical analysis of failure time data. New York: John Wiley & Sons, Inc., 1980.
15. Lancaster, T., & Intrator, O. Panel data with survival: Hospitalization of HIV patients. Department of Economics Working Paper No 95-36. Providence, RI: Brown University, 1995.
16. Laupacis, A., Feeney, D., Detsky, A. S., & Tugwell, R. X. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Canadian Medical Association Journal, 1992, 146, 473-81.
17. Mauskopf, J. A., Backhouse, M. E., Jones, D., et al. Synthetic surfactant for rescue treatment of respiratory distress syndrome in premature infants weighing from 700 to 1350 grams: Impact on hospital resource use and charges. Journal of Pediatrics, 1995, 126, 94-100.
18. McKenna, W. J., Swedberg, K., Zannad, F., et al. Experience of chronic intravenous epoprostenol infusion in end-stage cardiac failure: Results of FIRST. European Heart Journal, 1994, 15, 36A.
19. Proposal for standardization of some methodological aspects of cost-effectiveness analysis: Cost utility analyses, and cost-minimization analyses in the evaluation of health technologies and programs for the purpose of decision making in resource allocation. General Directorate of Services and Evaluation of Health Technologies and General Directorate of Insurance and Health Planning of the Ministry of Health and Consumption, Spain, 1994.
20. Schulman, K. A., Glick, H. A., Buxton, M., et al. The economic evaluation of the FIRST study: Design of a prospective analysis alongside a multinational phase III clinical trial. Controlled Clinical Trials, in press.
21. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New England Journal of Medicine, 1992, 327, 685-91.
22. Torrance, G. W. Measurement of health state utilities for economic appraisal. Journal of Health Economics, 1986, 5, 1-30.
23. Rutten-Van Mölken, M. P. M. H., Van Doorslaer, E. K. A., & Van Vliet, R. C. J. A. Statistical analysis of cost outcomes in a randomized controlled clinical trial. Health Economics, 1994, 3, 333-45.